General

No CPD Points

Course Summary

Dr Clare Bailey & Fiona Grey (13:09)

Lucentis, previously used to treat Wet AMD, has recently been licensed by NICE for the treatment of diabetic maculopathy – a complication of diabetes that affects the macular. Clare Bailey is a Consultant Ophthalmologist and Clinical director of the retinal treatment and research unit at Bristol Eye Hospital, and has been involved in the Royal College of Ophthalmologists guidelines for both age-related macular degeneration and diabetic retinopathy. Here, she talks to Fiona Grey about diabetic maculopathy and the prospects for its treatment with this new indication.

First published in DOCET OQ86 (2013).

    ◄Audio track (~13 mins)Evaluation►

    More information and references

    More information and references

    References:

    • Elman MJ, Aiello LP, Beck RW et al. (2010) Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117(6), 1064-1077
    • Mitchell P et al; RESTORE study group (2011) The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118(4), 615-25
    • Nguyen QD, Shah SM, Khwaja AA et al; READ-2 Study Group (2010) Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 117(11), 2146-2151
    • NICE guidelines concerning ranibizumab (Lucentis) for Diabetic macular oedema. [Accessed Jan 2018]
      ◄Audio track (~13 mins)Evaluation►